Transcranial Laser Therapy for Major Depressive Disorder
Maneno muhimu
Kikemikali
Maelezo
TLT has previously been evaluated in two large studies of people who have had a stroke. To date, TLT has been administered to over 550 people who have had a stroke. TLT has also been used in 10 people with MDD who were taking part in a research study. During this study, TLT was shown to relieve MDD symptoms without causing too many side effects.
The -Infrared Radiation (NIR) device is also marketed for wrinkles treatment, however it is experimental for the use in depression. An experimental device means that it is one that has not been approved by the U.S. Food and Drug Administration (FDA).
During this study, the investigators hope to better find out if NIR TLT is helpful for treating depression. The investigators will do this by comparing the effects of TLT ("active treatment") NIR device to a sham treatment (which is an inactive or "pretend" treatment) device. The sham ("pretend") device looks exactly like the NIR device but will not use a near-infrared radiation during the study visits. There are two sets of identical devices that will be used in this study, producing active and sham treatment, respectively. The devices work exactly the same when you are receiving active treatment and sham treatment, except that the devices will produce therapeutic transcranial LED energy during the active treatment sessions but it will not produce this LED energy during the sham treatment sessions.
The investigators hope to enroll about 30 subjects in this study at the Massachusetts General Hospital Depression Clinical and Research Program.
Tarehe
| Imethibitishwa Mwisho: | 09/30/2017 |
| Iliyowasilishwa Kwanza: | 02/16/2012 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 02/22/2012 |
| Iliyotumwa Kwanza: | 02/23/2012 |
| Sasisho la Mwisho Liliwasilishwa: | 10/23/2017 |
| Sasisho la Mwisho Lilichapishwa: | 11/28/2017 |
| Tarehe ya matokeo ya kwanza yaliyowasilishwa: | 01/08/2017 |
| Tarehe ya matokeo ya kwanza ya QC yaliyowasilishwa: | 10/23/2017 |
| Tarehe ya matokeo ya kwanza kuchapishwa: | 11/28/2017 |
| Tarehe halisi ya kuanza kwa masomo: | 01/31/2012 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 07/31/2015 |
| Tarehe ya Kukamilisha Utafiti: | 07/31/2015 |
Hali au ugonjwa
Uingiliaji / matibabu
Device: TLT Treatment Group 1
Device: TLT Treatment Group 2
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: TLT Treatment Group 1 The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks | Device: TLT Treatment Group 1 The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.
The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject. |
| Sham Comparator: TLT Treatment Group 2 The sham group will receive 2 treatments of the sham device per week for 8 weeks | Device: TLT Treatment Group 2 The sham device does not emit near-infrared radiation. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
| Jinsia Inastahiki Kujifunza | All |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - The subject is at least 18 years of age at screening, but has not had their 66th birthday. - SCID diagnosis of major depressive disorder (Structured Clinical Interview for Diagnostic Statistical Manual-IV) - HAM-D-17 >14 and < 25 - Women of child-bearing potential must use a double-barrier method for birth control (e.g. condoms with spermicide) if sexually active. - Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study. - The subject (and caregiver, if applicable) is willing to participate in this study for at least 8 weeks. - Subjects on an antidepressant will need to be on a stable dose for at least six weeks. Exclusion Criteria: - The subject is pregnant or lactating. - The subject failed two or more FDA-approved antidepressants during current episode - Subjects with less than 2 months MDD symptom free prior to current episode. - The subject used targeted psychotherapies for depression during current episode (support therapy or counseling are allowed) - Substance dependence or abuse in the past 6 months - Psychotic disorder or psychotic episode (current psychotic episode per SCID assessment) - Bipolar affective disorder (per SCID assessment) - Unstable medical illness, defined as any medical illness which has not been well-controlled with standard-of-care medications (e.g., insulin for diabetes mellitus, HCTZ for hypertension) - Active suicidal or homicidal ideation, as determined by CHRT screening - The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be directly below any of the procedure sites. - The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolised AVM, implantable shunt - Hakim valve). - Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (in US: Visudine (verteporfin) - for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer) |
Matokeo
Hatua za Matokeo ya Msingi
1. Change in Hamilton Depression Rating Scale (HAM-D 17) Score [Visit 1 (Baseline) and Visit 17 (Week 9); Pilot Phase: Visit 1 (Baseline) and Week 8]
Hatua za Matokeo ya Sekondari
1. Systematic Assessment for Treatment Emergent Events-systematic Inquiry (SAFTEE-SI) [Assessed at odd-numbered Visits 1-17. The single value to be analyzed is the number of distinct side effects that occurred at least once during these assessment visits for each subject.]
2. Number of Participants With Adverse Events [Visits 1, 3, 5, 7, 9, 11, 13, 15, and 17]
